Tevimbra by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals – Psychedelic Alpha

While obtaining a patent on the drug itself might be tricky—Merck had patented MDMA over a hundred years ago in 1912 after it found it

June 14, 2024

From potential to practice: A blueprint for responsible AI in healthcare

Researchers developed comprehensive AI guidelines to ensure safe, equitable, and effective integration into healthcare, with a case study highlighting ambient documentation applications.

December 3, 2024

Opinion | Lost in the Haze: What Would Rescheduling Marijuana Really Do?

Ryan Marino is a medical toxicologist, emergency physician, and addiction medicine specialist, and an associate professor in the Departments of Emergency Medicine and Psychiatry at

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.